The Balloon pump-assisted Coronary Intervention Study (BCIS-1): Rationale and design

American Heart Journal

Volumn 158, Issue 6, 2009, Pages

  Perera, Divaka ^a   Stables, Rodney ^b   Booth, Jean ^c   Thomas, Martyn ^a   Redwood, Simon ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b LIVERPOOL HEART AND CHEST HOSPITAL   (United Kingdom)

^c ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AORTA BALLOON; ARTICLE; BALLOON PUMP ASSISTED CORONARY INTERVENTION; CARDIOGENIC SHOCK; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUNTERPULSATION; DOUBLE BLIND PROCEDURE; FEMALE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT CONTRAINDICATION;

EID: 70549093082     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2009.09.015     Document Type: Article

References (27)

1. Nanas J.N., and Moulopoulos S.D. Counterpulsation: historical background, technical improvements, hemodynamic and metabolic effects. Cardiology 84 (1994) 156-167
2. Kern M.J., Aguirre F., Bach R., et al. Augmentation of coronary blood flow by intra-aortic balloon pumping in patients after coronary angioplasty. Circulation 87 (1993) 500-511
3. Barron H.V., Every N.R., Parsons L.S., et al. The use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction: data from the National Registry of Myocardial Infarction 2. Am Heart J 141 (2001) 933-939
4. Sjauw K.D., Engstrom A.E., Vis M.M., et al. A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines?. Eur Heart J 30 (2009) 459-468
5. Antman E.M., Anbe D.T., Armstrong P.W., et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 110 (2004) e82-e292
6. Van de W.F., Bax J., Betriu A., et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 29 (2008) 2909-2945
7. Singh M., Rihal C.S., Lennon R.J., et al. Bedside estimation of risk from percutaneous coronary intervention: the new Mayo Clinic risk scores. Mayo Clin Proc 82 (2007) 701-708
8. Chowdhary S., Ivanov J., Mackie K., et al. The Toronto score for in-hospital mortality after percutaneous coronary interventions. Am Heart J 157 (2009) 156-163
9. Bergelson B.A., Jacobs A.K., Cupples L.A., et al. Prediction of risk for hemodynamic compromise during percutaneous transluminal coronary angioplasty. Am J Cardiol 70 (1992) 1540-1545
10. O'Murchu B., Foreman R.D., Shaw R.E., et al. Role of intraaortic balloon pump counterpulsation in high risk coronary rotational atherectomy. J Am Coll Cardiol 26 (1995) 1270-1275
11. Stone G.W., Marsalese D., Brodie B.R., et al. A prospective, randomized evaluation of prophylactic intraaortic balloon counterpulsation in high risk patients with acute myocardial infarction treated with primary angioplasty. Second Primary Angioplasty in Myocardial Infarction (PAMI-II) Trial Investigators. J Am Coll Cardiol 29 (1997) 1459-1467
12. Brodie B.R., Stuckey T.D., Hansen C., et al. Intra-aortic balloon counterpulsation before primary percutaneous transluminal coronary angioplasty reduces catheterization laboratory events in high-risk patients with acute myocardial infarction. Am J Cardiol 84 (1999) 18-23
13. Briguori C., Sarais C., Pagnotta P., et al. Elective versus provisional intra-aortic balloon pumping in high-risk percutaneous transluminal coronary angioplasty. Am Heart J 145 (2003) 700-707
14. Mishra S., Chu W.W., Torguson R., et al. Role of prophylactic intra-aortic balloon pump in high-risk patients undergoing percutaneous coronary intervention. Am J Cardiol 98 (2006) 608-612
15. Ohman E.M., and Hochman J.S. Aortic counterpulsation in acute myocardial infarction: physiologically important but does the patient benefit?. Am Heart J 141 (2001) 889-892
16. Briguori C., Airoldi F., Chieffo A., et al. Elective versus provisional intraaortic balloon pumping in unprotected left main stenting. Am Heart J 152 (2006) 565-572
17. Smith Jr. S.C., Feldman T.E., Hirshfeld Jr. J.W., et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 47 (2006) e1-e121
18. Stone G.W., Ohman E.M., Miller M.F., et al. Contemporary utilization and outcomes of intra-aortic balloon counterpulsation in acute myocardial infarction: the benchmark registry. J Am Coll Cardiol 41 (2003) 1940-1945
19. Food US and Drug Administration. Required submission of safety and effectiveness information for certain class III devices. Available at: (2009). http://www.fda.gov/cdrh/classiii.html
20. Alpert J.S., Thygesen K., Antman E., et al. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 36 (2000) 959-969
21. Thygesen K., Alpert J.S., White H.D., et al. Universal definition of myocardial infarction. Circulation 116 (2007) 2634-2653
22. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group. N Engl J Med 312 (1985) 932-936
23. Califf R.M., Phillips III H.R., Hindman M.C., et al. Prognostic value of a coronary artery jeopardy score. J Am Coll Cardiol 5 (1985) 1055-1063
24. The World Medical Association. Declaration of Helsinki. Available at: (2009). http://www.wma.net/e/ethicsunit/helsinki.htm
25. US Food and Drug Administration. Guidances, information sheets, and important notices on good clinical practice in FDA-regulated clinical trials. Available at: (2009). http://www.fda.gov/oc/gcp/guidance.html
26. Ioannidis J.P., Karvouni E., and Katritsis D.G. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. J Am Coll Cardiol 42 (2003) 1406-1411
27. Andron M., Stables R.H., Egred M., et al. Impact of periprocedural creatine kinase-MB isoenzyme release on long-term mortality in contemporary percutaneous coronary intervention. J Invasive Cardiol 20 (2008) 108-112